| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Tufts University School of Medicine, Department of Anatomy and Cellular Biology, Boston, Massachusetts 02111
Address all correspondence and requests for reprints to: Ana M. Soto, M.D., Department of Anatomy and Cellular Biology, Tufts University School of Medicine, 136 Harrison Ave, Boston, Massachusetts 02111. E-mail: ASOTO{at}Opal.Tufts.Edu
Sex steroids control the proliferation of their target cells through two different pathways: 1) proliferative response (Step-1); and 2) inhibition of cell proliferation (Step-2). Mechanisms of cell proliferation regulation are incompletely understood; however, there is general agreement with the notion that sex steroid receptors play an important role in the control of the proliferation of sex steroid target cells. To test this hypothesis, a full human androgen receptor (AR) vector was transfected into human breast cancer MCF7 cells. The cloned cells that stably express the AR, called MCF7-AR1 cells, contained approximately five times more AR than the wild-type MCF7 cells from which they were derived. These AR-transfected cells retained their capacity to proliferate when estrogens were added to 10% charcoal-dextran stripped human serum but did not acquire the ability to proliferate when androgens were added to this medium. In serumless medium (ITDME), these cells proliferated maximally, as MCF7 cells did; however, natural and synthetic androgens prevented the AR-transfected cells from proliferating. Inhibition of cell proliferation occurred when physiological androgen concentrations (1 nM) were added to ITDME; this effect was almost completely reversed by Casodex, a synthetic androgen antagonist. Under the effect of androgens added to ITDME, MCF7-AR1 cells were arrested in the G0/G1 phase within 24 h. These data suggest that: 1) the androgen-induced inhibition of cell proliferation (Step-2) is AR-mediated; and 2) the AR may be necessary, but not sufficient, to mediate the androgen-induced proliferative response (Step-1).
This article has been cited by other articles:
![]() |
P. Roy, M. Alevizaki, and I. Huhtaniemi In vitro bioassays for androgens and their diagnostic applications Hum. Reprod. Update, January 1, 2008; 14(1): 73 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. O von Bueren, R. Ma, M. Schlumpf, and W. Lichtensteiger Salbutamol exhibits androgenic activity in vitro Br. J. Sports Med., December 1, 2007; 41(12): 874 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Perez-Palacios, R. Santillan, R. Garcia-Becerra, E. Borja-Cacho, F. Larrea, P. Damian-Matsumura, L. Gonzalez, and A. E Lemus Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern. J. Endocrinol., September 1, 2006; 190(3): 805 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. W. Rokhlin, R. B. Glover, N. V. Guseva, A. F. Taghiyev, K. G. Kohlgraf, and M. B. Cohen Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor-Positive Prostate Cancer Cells Mol. Cancer Res., February 1, 2006; 4(2): 113 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yeh, Y.-C. Hu, P.-H. Wang, C. Xie, Q. Xu, M.-Y. Tsai, Z. Dong, R.-S. Wang, T.-H. Lee, and C. Chang Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor J. Exp. Med., December 15, 2003; 198(12): 1899 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Liede, W. Zhang, M. L. D. L. Matsuda, A. Tan, and S. A. Narod Androgen Receptor Gene Polymorphism and Breast Cancer Susceptibility in the Philippines Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 848 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Yeap, D. C. Voon, J. P. Vivian, R. K. McCulloch, A. M. Thomson, K. M. Giles, M. F. Czyzyk-Krzeska, H. Furneaux, M. C. J. Wilce, J. A. Wilce, et al. Novel Binding of HuR and Poly(C)-binding Protein to a Conserved UC-rich Motif within the 3'-Untranslated Region of the Androgen Receptor Messenger RNA J. Biol. Chem., July 19, 2002; 277(30): 27183 - 27192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Maffini, P. Geck, C. E. Powell, C. Sonnenschein, and A. M. Soto Mechanism of Androgen Action on Cell Proliferation: AS3 Protein as a Mediator of Proliferative Arrest in the Rat Prostate Endocrinology, July 1, 2002; 143(7): 2708 - 2714. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Soto and C. Sonnenschein The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death J Natl Cancer Inst, November 21, 2001; 93(22): 1673 - 1675. [Full Text] [PDF] |
||||
![]() |
Y. Giguere, E. Dewailly, J. Brisson, P. Ayotte, N. Laflamme, A. Demers, V.-I. Forest, S. Dodin, J. Robert, and F. Rousseau Short Polyglutamine Tracts in the Androgen Receptor Are Protective against Breast Cancer in the General Population Cancer Res., August 1, 2001; 61(15): 5869 - 5874. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Nathanson and B. L. Weber 'Other' breast cancer susceptibility genes: searching for more holy grail Hum. Mol. Genet., April 1, 2001; 10(7): 715 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Levine and J. Boyd The Androgen Receptor and Genetic Susceptibility to Ovarian Cancer: Results from a Case Series Cancer Res., February 1, 2001; 61(3): 908 - 911. [Abstract] [Full Text] |
||||
![]() |
F.M. Lyng, G.R. Jones, and F.F.G. Rommerts Rapid Androgen Actions on Calcium Signaling in Rat Sertoli Cells and Two Human Prostatic Cell Lines: Similar Biphasic Responses Between 1 Picomolar and 100 Nanomolar Concentrations Biol Reprod, September 1, 2000; 63(3): 736 - 747. [Abstract] [Full Text] |
||||
![]() |
P. Geck, M. V. Maffini, J. Szelei, C. Sonnenschein, and A. M. Soto Androgen-induced proliferative quiescence in prostate cancer cells: The role of AS3 as its mediator PNAS, August 29, 2000; 97(18): 10185 - 10190. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Zatelli, R. Rossi, and E. C. degli Uberti Androgen Influences Transforming Growth Factor-{beta}1 Gene Expression in Human Adrenocortical Cells J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 847 - 852. [Abstract] [Full Text] |
||||
![]() |
A. M. Dunning, S. McBride, J. Gregory, F. Durocher, N. A. Foster, C. S. Healey, N. Smith, P. D. P. Pharoah, R. N. Luben, D. F. Easton, et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer Carcinogenesis, November 1, 1999; 20(11): 2131 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Prehn On the Prevention and Therapy of Prostate Cancer by Androgen Administration Cancer Res., September 1, 1999; 59(17): 4161 - 4164. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Yeap, R. G. Krueger, and P. J. Leedman Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells Endocrinology, July 1, 1999; 140(7): 3282 - 3291. [Abstract] [Full Text] |
||||
![]() |
S. Yeh, Y.-C. Hu, M. Rahman, H.-K. Lin, C.-L. Hsu, H.-J. Ting, H.-Y. Kang, and C. Chang Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells PNAS, October 10, 2000; 97(21): 11256 - 11261. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |